Activating transcription factor 4 increases chemotherapeutics resistance of human hepatocellular carcinoma

Cancer Biology and Therapy

Volumn 13, Issue 6, 2012, Pages 435-442

  Zhang, Zhuhong ^a,b   Yin, Jing ^a   Zhang, Chunyan ^a   Liang, Ning ^a   Bai, Nan ^a   Chang, Antao ^a   Liu, Yanhua ^a   Li, Zongjin ^a   Tan, Xiaoyue ^a   Li, Na ^a   Lv, Dan ^a   Xiang, Rong ^a   Tian, Yaping ^b   Liu, Chenghu ^a  

^a NANKAI UNIVERSITY   (China)

^b CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Apoptosis; ATF4; Chemoresistance; Glutathione; Hepatoma

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 4; CISPLATIN; GLUTATHIONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOSYNTHESIS; CANCER CELL CULTURE; CANCER RESISTANCE; CONTROLLED STUDY; CYTOTOXICITY; DRUG SENSITIVITY; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; PROTEIN EXPRESSION;

EID: 84860254347     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.19295     Document Type: Article

References (32)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics 2002. CA Cancer J Clin 2005; 55:74-108; PMID:15761078; http://dx.doi.org/10.3322/ canjclin.55.2.74.
2. De Flora S, Bonanni P. The prevention of infection-associated cancers. Carcinogenesis 2011; 32:787-95; PMID:21436188; http://dx.doi.org/10.1093/carcin/ bgr054.
3. Leong TY, Leong AS. Epidemiology and carcinogenesis of hepatocellular carcinoma. HPB (Oxford) 2005; 7:5-15; http://dx.doi.org/10.1080/ 13651820410024021; PMID:18333156.
4. Rampone B, Schiavone B, Martino A, Viviano C, Confuorto G. Current management strategy of hepatocellular carcinoma. World J Gastroenterol 2009; 15:3210-6; http://dx.doi.org/10.3748/wjg.15.3210; PMID:19598295.
5. Welzel TM, Graubard BI, Zeuzem S, El-Serag HB, Davila JA, McGlynn KA. Metabolic syndrome increases the risk of primary liver cancer in the United States: A population-based case-control study. Hepatology 2011; 54:463-71; PMID:21538440; http://dx.doi.org/10.1002/hep.24397.
6. Han KH, Seong J, Kim JK, Ahn SH, Lee Y, Chon CY. Pilot clinical trial of localized concurrent chemoradiation therapy for locally advanced hepatocellular carcinoma with portal vein thrombosis. Cancer 2008; 113:995-1003; http://dx.doi.org/10.1002/cncr.23684;PMID:18615601.
7. Morise Z, Sugioka A, Fujita J, Hoshimoto S, Kato T, Ikeda M. S-1 plus cisplatin combination therapy for the patients with primary liver carcinomas. Hepatogastroenterology 2007; 54:2315-8; PMID:18265655.
8. Ye CG, Wu WK, Yeung JH, Li HT, Li ZJ, Wong CC, et al. Indomethacin and SC236 enhance the cytotoxicity of doxorubicin in human hepatocellular carcinoma cells via inhibiting P-glycoprotein and MRP1 expression. Cancer Lett 2011; 304:90-6; PMID:21377266; http://dx.doi.org/10.1016/j.canlet.2011.01.025.
9. Fujii R, Mutoh M, Niwa K, Yamada K, Aikou T, Nakagawa M, et al. Active efflux system for cisplatin in cisplatin-resistant human KB cells. Jpn J Cancer Res 1994; 85:426-33; PMID:8200854; http://dx.doi.org/10.1111/j.1349-7006.1994. tb02376.x.
10. Lai GM, Ozols RF, Young RC, Hamilton TC. Effect of glutathione on DNA repair in cisplatin-resistant human ovarian cancer cell lines. J Natl Cancer Inst 1989; 81:535-9; http://dx.doi.org/10.1093/jnci/81.7.535; PMID:2493524.
11. Chaney SG, Sancar A. DNA repair: enzymatic mechanisms and relevance to drug response. J Natl Cancer Inst 1996; 88:1346-60; http://dx.doi.org/10.1093/ jnci/88.19.1346; PMID:8827012.
12. Sedletska Y, Giraud-Panis MJ, Malinge JM. Cisplatin is a DNA-damaging antitumour compound triggering multifactorial biochemical responses in cancer cells: importance of apoptotic pathways. Curr Med Chem Anticancer Agents 2005; 5:251-65; PMID:15992353; http://dx.doi.org/10.2174/1568011053765967.
13. Zhu AX, El-Khoueiry A, Llovet JM. Accomplishments in 2008 in the management of hepatobiliary cancers. Gastrointest Cancer Res 2009; 3:28-36; PMID:20011562.
14. Wang Q, Zheng XL, Yang L, Shi F, Gao LB, Zhong YJ, et al. Reactive oxygen species-mediated apoptosis contributes to chemosensitization effect of saikosaponins on cisplatin-induced cytotoxicity in cancer cells. J Exp Clin Cancer Res 2010; 29:159; http://dx.doi.org/10.1186/1756-9966-29-159; PMID:21143894.
15. Rutkowski DT, Kaufman RJ. All roads lead to ATF4. Dev Cell 2003; 4:442-4; http://dx.doi.org/10.1016/S1534-5807(03)00100-X; PMID:12689582.
16. Armstrong JL, Flockhart R, Veal GJ, Lovat PE, Redfern CP. Regulation of endoplasmic reticulum stress-induced cell death by ATF4 in neuroectodermal tumor cells. J Biol Chem 2010; 285:6091-100; http://dx.doi.org/10.1074/jbc.M109. 014092; PMID:20022965.
17. Ameri K, Hammond EM, Culmsee C, Raida M, Katschinski DM, Wenger RH, et al. Induction of activating transcription factor 3 by anoxia is independent of p53 and the hypoxic HIF signalling pathway. Oncogene 2007; 26:284-9; http://dx.doi.org/10.1038/sj.onc.1209781; PMID:16847457.
18. Bi M, Naczki C, Koritzinsky M, Fels D, Blais J, Hu N, et al. ER stress-regulated translation increases tolerance to extreme hypoxia and promotes tumor growth. EMBO J 2005; 24:3470-81; http://dx.doi.org/10.1038/sj.emboj. 7600777; PMID:16148948.
19. Chakraborty G, Jain S, Kundu GC. Osteopontin promotes vascular endothelial growth factor-dependent breast tumor growth and angiogenesis via autocrine and paracrine mechanisms. Cancer Res 2008; 68:152-61; http://dx.doi.org/10.1158/0008-5472.CAN-07-2126; PMID:18172307.
20. Tanabe M, Izumi H, Ise T, Higuchi S, Yamori T, Yasumoto K, et al. Activating transcription factor 4 increases the cisplatin resistance of human cancer cell lines. Cancer Res 2003; 63:8592-5; PMID:14695168.
21. Igarashi T, Izumi H, Uchiumi T, Nishio K, Arao T, Tanabe M, et al. Clock and ATF4 transcription system regulates drug resistance in human cancer cell lines. Oncogene 2007; 26:4749-60; http://dx.doi.org/10.1038/sj.onc.1210289; PMID:17297441.
22. Ameri K, Lewis CE, Raida M, Sowter H, Hai T, Harris AL. Anoxic induction of ATF-4 through HIF-1-independent pathways of protein stabilization in human cancer cells. Blood 2004; 103:1876-82; http://dx.doi.org/10.1182/blood-2003-06- 1859; PMID:14604972.
23. Harding HP, Zhang Y, Zeng H, Novoa I, Lu PD, Calfon M, et al. An integrated stress response regulates amino acid metabolism and resistance to oxidative stress. Mol Cell 2003; 11:619-33; http://dx.doi.org/10.1016/S1097- 2765(03)00105-9; PMID:12667446.
24. Namba T, Hoshino T, Tanaka K, Tsutsumi S, Ishihara T, Mima S, et al. Upregulation of 150-kDa oxygen-regulated protein by celecoxib in human gastric carcinoma cells. Mol Pharmacol 2007; 71:860-70; http://dx.doi.org/10.1124/mol. 106.027698; PMID:17167033.
25. Shringarpure R, Catley L, Bhole D, Burger R, Podar K, Tai YT, et al. Gene expression analysis of B-lymphoma cells resistant and sensitive to bortezomib. Br J Haematol 2006; 134:145-56; http://dx.doi.org/10.1111/j.1365-2141.2006. 06132.x; PMID:16846475.
26. Niedner H, Christen R, Lin X, Kondo A, Howell SB. Identification of genes that mediate sensitivity to cisplatin. Mol Pharmacol 2001; 60:1153-60; PMID:11723219.
27. Selvakumaran M, Pisarcik DA, Bao R, Yeung AT, Hamilton TC. Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines. Cancer Res 2003; 63:1311-6; PMID:12649192.
28. Mabuchi S, Ohmichi M, Nishio Y, Hayasaka T, Kimura A, Ohta T, et al. Inhibition of NFkappaB increases the efficacy of cisplatin in in vitro and in vivo ovarian cancer models. J Biol Chem 2004; 279:23477-85; http://dx.doi.org/ 10.1074/jbc.M313709200; PMID:15026414.
29. Garrido N, Pérez-Martos A, Faro M, Lou-Bonafonte JM, Fernández-Silva P, López-Pérez MJ, et al. Cisplatin-mediated impairment of mitochondrial DNA metabolism inversely correlates with glutathione levels. Biochem J 2008; 414:93-102; PMID:18426391; http://dx.doi.org/10.1042/BJ20071615.
30. Choy CS, Cheah KP, Chiou HY, Li JS, Liu YH, Yong SF, et al. Induction of hepatotoxicity by sanguinarine is associated with oxidation of protein thiols and disturbance of mitochondrial respiration. J Appl Toxicol 2008; 28:945-56; http://dx.doi.org/10.1002/jat.1360; PMID:18548746.
31. Grant CE, Gao M, DeGorter MK, Cole SP, Deeley RG. Structural determinants of substrate specificity differences between human multidrug resistance protein (MRP) 1 (ABCC1) and MRP3 (ABCC3). Drug Metab Dispos 2008; 36:2571-81; http://dx.doi.org/10.1124/dmd.108.022491; PMID:18775981.
32. Fung H, Liu P, Demple B. ATF4-dependent oxidative induction of the DNA repair enzyme Ape1 counteracts arsenite cytotoxicity and suppresses arsenite-mediated mutagenesis. Mol Cell Biol 2007; 27:8834-47; http://dx.doi.org/10.1128/MCB.00974-07; PMID:17938202